[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100443851":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":36,"centralContacts":41,"locations":50,"responsibleParty":69,"collaborators":30,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":30,"eligibilityCriteria":77,"healthyVolunteers":74,"sex":78,"minAge":79,"maxAge":30,"enrollmentInfo":80,"targetDuration":30,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":105,"overallStatus":113,"whyStopped":30,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Xi'an Jiaotong University","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A (drug treatment group)","ACTIVE_COMPARATOR","Group A (drug treatment group) : Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.",[13],"Drug: chemotherapy, targeted therapeutics, immunotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B (radiotherapy group)","EXPERIMENTAL","IFRT, IMRT or SBRT is applied. Irradiation techniques and doses can be selected based on the previous experience of each center, but all patients enrolled within the center need to be consistent.",[19],"Radiation: IFRT, IMRT or SBRT",{"label":21,"type":16,"description":22,"interventionNames":23},"Group C (radiotherapy + drug group)","Drug therapy is the same as group A; IFRT is the same as group B.",[13,19],[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","chemotherapy, targeted therapeutics, immunotherapy","Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.",[9,21],null,{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":30},"RADIATION","IFRT, IMRT or SBRT","IFRT（involving field radiotherapy） IMRT （ intensity modulated radiation therapy） SBRT （stereotactic body radiation therapy）",[15,21],[37],{"name":38,"affiliation":39,"role":40},"Zi Liu, Ph.d","First Affiliated Hospital Xi'an Jiaotong University","PRINCIPAL_INVESTIGATOR",[42,46],{"name":38,"role":43,"phone":44,"phoneExt":30,"email":45},"CONTACT","86-18991232167","liuzmail@163.com",{"name":47,"role":43,"phone":48,"phoneExt":30,"email":49},"Jing Zhang, M.D","86-18220761865","zj2020email@163.com",[51],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"The First Affiliated Hospital of Xi'an Jiao Tong University","RECRUITING","Xi'an","Shaanxi","710061","China","CN",{"type":60,"coordinates":61},"Point",[62,63],108.92861,34.25833,{"lat":63,"lon":62},[66],{"name":67,"role":43,"phone":68,"phoneExt":30,"email":45},"zi liu, Ph.D","+8613630223132",{"type":40,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Liu Zi","Professor","100443851","efficacy-and-safety-of-involving-field-radiotherapy-in-the-oligo-lesionsmetastasisrecurrentrefractory-of-ovarian-cancer-100443851",false,"NCT05059782","Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis\u002FRecurrent\u002FRefractory) of Ovarian Cancer","Inclusion Criteria:\n\n1. Age ≥18;\n2. Evidence of histological diagnosis of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)\n3. Pathology or imaging suggested recurrence, with measurable lesions, and the number of lesions ≤3;\n4. No serious hematopoietic dysfunction, abnormal heart, lung, liver, kidney and immune deficiency\n5. Cooperative Oncology Group-Status (ECOG Status) score 0-2;\n6. Expected survival ≥3 months;\n7. Feasible abdomen and pelvic cavity MRI\u002FCT;\n8. Good compliance, signed informed consent voluntarily.\n\nExclusion Criteria:\n\n1. Previous radiotherapy at the target lesion site;\n2. History of active inflammatory bowel disease or severe stomach and duodenal ulcers;\n3. Human immunodeficiency virus (HIV) infected persons;\n4. active hepatitis b (HBVDNA quantitative test results exceed the lower limit), or HCV infection (HCVRNA quantitative test results exceed the lower limit);\n5. suffering from serious underlying diseases, including but not limited to active infections requiring systemic medication:\n6. patients with a history of other malignant tumors (except cured basal cell carcinoma of the skin);\n7. neurological or mental disorders that affect cognitive ability;\n8. Patients whose lesions have been evaluated by the investigator and cannot be treated with external irradiation or endovascular radiation therapy;\n9. those who cannot follow up regularly as prescribed by the doctor;\n10. Other reasons not suitable for participating in this study as judged by the researcher.","FEMALE","18 Years",{"count":81,"type":82},150,"ESTIMATED","INTERVENTIONAL",[85],"NA","In this study, The researchers sought to explore the efficacy and safety of involving field radiotherapy in the oligo-metastatic\u002Frecurrent\u002Frefractory ovarian cancer patients among different groups which include drug therapy alone, radiotherapy alone, and drug therapy plus radiotherapy by inviting clinical multi-center participation.",[88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104],"Ovarian Cancer","Neoplasm, Ovarian","Ovarian Neoplasm","Ovary Neoplasms","Neoplasm, Ovary","Neoplasms, Ovary","Ovary Neoplasm","Neoplasms, Ovarian","Ovary Cancer","Cancer, Ovarian Stromal","Cancers, Ovary","Ovary Cancers","Cancer, Ovarian","Cancers, Ovarian","Ovarian Cancers","Cancer of Ovary","Cancer of the Ovary",[106,107,108,109,110,111,112],"oligo-lessions","metastasis","recurrent","refractory","ovarian cancer","radiotherapy","chemotherapy","UNKNOWN","2021-09-25",{"date":116,"type":117},"2021-09-28","ACTUAL",{"date":119,"type":82},"2021-10-10",{"date":121,"type":82},"2024-09-01",{"name":5,"class":6},1]